NCT07038824View on ClinicalTrials.gov

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 1, 2029

Study Completion Date

March 1, 2029

Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DRUG

ENTR-601-45

intravenous infusion

DRUG

ENTR-601-45 - matching placebo

intravenous infusion

Trial Locations (15)

3000

UZ Leuven, Leuven

9000

University Hospital Gent, Ghent

University Hospital Gent, Ghent

20132

IRCCS Ospedale San Raffaele, Milan

00165

Ospedale Pediatrico Bambino Gesu, Rome

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome

2333 ZA

Leids Universitair Medisch Centrum, Leiden

6525 GA

Stichting Radboud Universitair Medisch Centrum, Nijmegen

08035

Hospital Universitario Vall d'Hebron, Barcelona

08950

Hospital Sant Joan de Deu, Barcelona

LS1 3EX

Leeds General Infirmary, Leeds

L122AP

Alder Hey Children's NHS Foundation Trust, Liverpool

WC1N 3JH

Great Ormond Street Hospital for Children, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

Sponsors
All Listed Sponsors
lead

Entrada Therapeutics, Inc.

INDUSTRY

NCT07038824 - A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | Biotech Hunter | Biotech Hunter